Home
Live Updates
PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab) : comparemela.com
PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)
DAEJEON, South Korea, Dec. 12, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the developm...
Related Keywords
Australia ,
United States ,
Daejeon ,
Taejon Gwangyoksi ,
South Korea ,
Jin San Yoo ,
Linkedin ,
Business Development Team ,
Ir Pr Team ,
Pharmabcine Inc ,
Merck Co Inc ,
Youtube ,
Merck Sharp Dohme ,
Prnewswire Pharmabcine Inc ,
Triple Negative Breast Cancer ,
Merck Sharp ,
V Domain Ig Suppressor ,
Myeloid Derived Suppressor Cells ,
Clinical Trial Application ,
Tumor Microenvironment ,
Age Related Macular Degeneration ,
comparemela.com © 2020. All Rights Reserved.